Revolution Medicines (NASDAQ: RVMD) — Company Overview, News & Financial Data
Revolution Medicines develops targeted therapies for cancer, focusing on precision oncology and disrupting pathways critical to tumor survival.
Revolution Medicines
Revolution Medicines is a clinical-stage oncology company focused on discovering and developing novel targeted therapies for patients with RAS-addicted cancers. The company leverages its proprietary tri-complex platform to target the active RAS(ON) state of RAS proteins, which drive roughly thirty percent of human cancer diagnoses. Its research and development pipeline includes investigational oral small-molecule inhibitors designed as monotherapies and combination regimens for solid tumors. Key clinical programs target mutant forms such as RAS G12C, RAS G12D, and broad-spectrum RAS variants across non-small cell lung cancer, pancreatic cancer, and colorectal cancer.
Snapshot
Operations
Products and/or services of Revolution Medicines
- RAS Multi-Selective Inhibitors: Investigational oral small-molecule therapies targeting active RAS(ON) proteins across multiple oncogenic mutations, undergoing clinical trials for advanced solid tumors including pancreatic ductal adenocarcinoma and non-small cell lung cancer.
- RAS G12C-Selective Inhibitors: Targeted investigational oral compounds designed to bind directly to active KRAS G12C mutants via tri-complex formation, currently evaluated in clinical trials as monotherapy and in targeted combination therapies for solid tumors.
- RAS G12D-Selective Inhibitors: Oral small-molecule candidates specifically targeting the active state of KRAS G12D mutated proteins, currently evaluated in ongoing clinical trials for gastrointestinal and lung malignancies, including pancreatic ductal adenocarcinoma and colorectal carcinoma.
- Tri-Complex Discovery Platform: Proprietary structure-based drug discovery platform utilizing intracellular immunophilin chaperones, such as cyclophilin A, to non-covalently engage and inhibit previously undruggable active RAS(ON) signaling complexes across various human cancer cell models.
- Mutant-Selective Preclinical Pipeline: Early-stage research and discovery programs focused on developing targeted inhibitors against distinct oncogenic RAS variants, including G12V, G13D, and Q61 mutations, to broaden coverage across RAS-driven oncology indications.
- Combination Regimen Clinical Programs: Development initiatives evaluating investigational RAS(ON) candidates in combination with existing standard-of-care therapies, checkpoint inhibitors, and complementary targeted agents to prevent therapeutic resistance and improve anti-tumor responses.
Revolution Medicines executive team
- Dr. Mark A. Goldsmith M.D., Ph.D.CEO, President & Chairman
- Mr. Jack AndersChief Financial Officer
- Ms. Margaret A. Horn J.D.Chief Operating Officer
- Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.President of Research & Development
- Ms. Xiaolin WangExecutive Vice President of Development
- Dr. Martin D. Burke M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory Board
- Dr. Michael A. Fischbach Ph.D.Academic Co-Founder & Member of Scientific Advisory Board
- Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory Board
- Mr. Walter Reiher Ph.D.Chief Information Officer
- Ms. Jan Smith Ph.D.Chief Scientific Officer